836TiP - GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

M Shah,J.A Ajani,S.-E Al-Batran,Y.-J Bang,D.V Catenacci,P Enzinger,D Ilson,S Kim,F Lordick,K Shitara,E Van Cutsem,A Arozullah,J.W Park,R.-H Xu

doi:10.1093/annonc/mdz247.162

836TiP - GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

M Shah, J.A Ajani + Show 12 more

Open Access

https://doi.org/10.1093/annonc/mdz247.162

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 6	License type: elsevier-specific

Affiliation: KU Leuven, National Cancer Center Hospital East, Seoul National University Hospital, MedStar Georgetown University Hospital, Dana-Farber Cancer Institute, Krankenhaus Nordwest, Sun Yat-sen University Cancer Center

#Research Grant #Capecitabine + Oxaliplatin + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

836TiP - GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Full Text